Valneva updates vaccine agreement with GSK
Lyon | 9 February 2016

Valneva has signed a new R&D collaboration with GlaxoSmithKline for the development of new influenza vaccines.

Under the agreement, Valneva will conduct the R&D programme on behalf of GlaxoSmithKline to develop and improve upstream processes that will serve the manufacturing of influenza vaccines based on its EB66 cell line.

Valneva’s EB66 cell line is a platform for vaccine production, derived from duck embryonic stem cells.

The programme received the support of the US Department of Health and Services, which encourages the development of new vaccine technologies through its arm the Biomedical Advanced Research and Development Authority (BARDA).

In May 2007, Valneva granted an exclusive commercial licence to GlaxoSmithKline to develop and market pandemic and seasonal human influenza vaccines using its EB66 cell line.

Under the 2007 agreement, Valneva is entitled to receive milestone payments as well as royalties associated with future sales.

Under the new collaboration, Valneva has secured additional research fees.

Thomas Lingelbach, president of Valneva, said: “We are pleased to extend our long term collaboration with GlaxoSmithKline and we are honoured to see BARDA supporting the GlaxoSmithKline vaccine approach based on our EB66 cell platform.”

Author: Tammy Facey

More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization